A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors

被引:45
作者
Bhattacharjee, AK
Geyer, JA
Woodard, CL
Kathcart, AK
Nichols, DA
Prigge, ST
Li, ZY
Mott, BT
Waters, NC
机构
[1] Walter Reed Army Inst Res, Dept Med Chem, Div Expt Therapeut, Dept Med Chem, Silver Spring, MD 20910 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Malaria Res Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA
关键词
D O I
10.1021/jm040108f
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cell division cycle is regulated by a family of cyclin-dependent protein kinases (CDKs) that are functionally conserved among many eukaryotic species. The characterization of plasmodial. CDKs has identified them as a leading antimalarial drug target in our laboratory. We have developed a three-dimensional QSAR pharmacophore model for inhibition of a Plasmodium falciparum CDK, known as Pfmrk, from a set of fifteen structurally diverse kinase inhibitors with a wide range of activity. The model was found to contain two hydrogen bond acceptor functions and two hydrophobic sites including one aromatic-ring hydrophobic site. Although the model was not developed from X-ray structural analysis of the known CDK2 structure, it is consistent with the structure-functional requirements for binding of the CDK inhibitors in the ATP binding pocket. Using the model as a template, a search of the in-house three-dimensional multiconformer database resulted in the discovery of sixteen potent Pfmrk inhibitors. The predicted inhibitory activities of some of these Pfmrk inhibitors from the molecular model agree exceptionally well with the experimental inhibitory values from the in vitro CDK assay.
引用
收藏
页码:5418 / 5426
页数:9
相关论文
共 37 条
  • [1] *ACC INC, CER TOPK
  • [2] Structure-activity relationship study of antimalarial indolo [2,1-b]quinazoline-6,12-diones (tryptanthrins). Three dimensional pharmacophore modeling and identification of new antimalarial candidates
    Bhattacharjee, AK
    Hartell, MG
    Nichols, DA
    Hicks, RP
    Stanton, B
    van Hamont, JE
    Milhous, WK
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2004, 39 (01) : 59 - 67
  • [3] Breman JG, 2001, AM J TROP MED HYG, V64, P1
  • [4] Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity
    Brown, NR
    Noble, MEM
    Lawrie, AM
    Morris, MC
    Tunnah, P
    Divita, G
    Johnson, LN
    Endicott, JA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (13) : 8746 - 8756
  • [5] Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine
    DeAzevedo, WF
    Leclerc, S
    Meijer, L
    Havlicek, L
    Strnad, M
    Kim, SH
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2): : 518 - 526
  • [6] Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
    deAzevedo, WF
    MuellerDieckmann, HJ
    SchulzeGahmen, U
    Worland, PJ
    Sausville, E
    Kim, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) : 2735 - 2740
  • [7] CRYSTAL-STRUCTURE OF CYCLIN-DEPENDENT KINASE-2
    DEBONDT, HL
    ROSENBLATT, J
    JANCARIK, J
    JONES, HD
    MORGAN, DO
    KIM, SH
    [J]. NATURE, 1993, 363 (6430) : 595 - 602
  • [8] *DIV EXP THER WALT, CHEM INF SYST
  • [9] Cyclin-dependent kinase homologues of Plasmodium falciparum
    Doerig, C
    Endicott, J
    Chakrabarti, D
    [J]. INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2002, 32 (13) : 1575 - 1585
  • [10] Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics
    Fischer, PM
    Lane, DP
    [J]. CURRENT MEDICINAL CHEMISTRY, 2000, 7 (12) : 1213 - 1245